72 citations
,
November 2015 in “Multiple Sclerosis and Related Disorders” This study concluded that teriflunomide has a consistent and manageable safety profile, with common mild-to-moderate adverse events and no new safety concerns identified over up to 12 years of treatment.
5 citations
,
August 2018 in “Neurology and Therapy” In this observational study, most patients with multiple sclerosis on teriflunomide who experienced hair thinning reported it as mild or moderate and largely recovered while continuing treatment.
29 citations
,
January 2016 in “CNS drugs” This review of teriflunomide for relapsing-remitting multiple sclerosis examines its clinical and safety outcomes, finding it significantly reduces relapse rates and disability progression while being generally well-tolerated.
Defective protein folding due to a mutation is key in ANE syndrome.